Détail - canceropole-wordpress

EXPRESSION EVALUATED BY DIGITAL IMAGE ANALYSIS TECHNIQUES OF PRAME MORE THAN MCM6 IS ASSOCIATED WITH POOR PROGNOSIS IN NEUROBLASTOMA: A PILOT STUDY WITH 84 CASES.

Touioui S, Desandes E, Jannot L, Mansuy L, Clabaut D, Peuchmaur M, Rioux-Leclercq N, Khneisser P, Thiebaut PA, Gallo M, Nemos C, Schleiermacher G, Chastagner P, Sartelet H

Hum Pathol. 2025 01 20;:105718

Centralized Investigator Review of Radiological and Functional Imaging Reports in Real-World Oncology Studies: The SACHA-France Experience.

Berlanga P, Aerts I, Corradini N, Ndounga-Diakou LA, Entz-Werle N, Ducassou S, André N, Sevrin F, Chastagner P, Puiseux C, Cleirec M, Plantaz D, De Carli E, Gambart M, Khanfar C, Thouvenin S, Petit A, Klein S, Briandet C, Millot F, Pluchart C, Reguerre Y, Schneider P, Serre J, Halfon-Domenech C, Carausu L, Piguet C, Saumet L, Benadiba J, Abbou S, Laghouati S, Geoerger B, Vassal G

Pediatr Blood Cancer. 2024 11 19;:e31449

Deciphering Natural Killer Cell Cytotoxicity Against Medulloblastoma in vitro and in vivo: Implications for Immunotherapy.

Gauthier M, Pierson J, Moulin D, Mouginot M, Bourguignon V, Rhalloussi W, Vincourt JB, Dumas D, Bensoussan D, Chastagner P, Boura C, Decot V

Immunotargets Ther. 2024 06 26;13:319-333

Fertility Assessment after Ovarian Transposition in Children and Young Women Treated for a Malignant Tumor.

Valduga J, Desmules G, Claude L, Chastagner P, Bernier-Chastagner V, Marec-Berard P, Rousset-Jablonski C

Curr Oncol. 2024 05 31;31(6):3177-3188

Dosimetric analysis of hearing loss after cranial radiation therapy in children: A single-institution study from the french national registry pediart.

Gehin W, Chastagner P, Mansuy L, Bernier-Chastagner V

Radiother Oncol. 2024 05 26;:110346

Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome.

Pincez T, Fernandes H, Fahd M, Pasquet M, Chahla WA, Granel J, Ducassou S, Thomas C, Garnier N, Jeziorski E, Bayart S, Chastagner P, Cheikh N, Guitton C, Paillard C, Lejeune J, Millot F, Li-Thiao Te V, Mallebranche C, Pellier I, Castelle M, Armari-Alla C, Carausu L, Piguet C, Benadiba J, Pluchart C, Stephan JL, Deparis M, Briandet C, Doré E, Marie-Cardine A, Barlogis V, Leverger G, Héritier S, Aladjidi N, Leblanc T

Am J Hematol. 2024 04 23;:

Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.

Chaix J, Schleiermacher G, Corradini N, André N, Thebaud E, Gambart M, Defachelles AS, Entz-Werle N, Chastagner P, De Carli É, Ducassou S, Landman-Parker J, Adam-de-Beaumais T, Larive A, Michiels S, Vassal G, Valteau-Couanet D, Geoerger B, Berlanga P

Eur J Cancer. 2024 02 15;201:113923

Antinuclear antibodies associated auto-immune cytopenia in childhood is a risk factor for systemic lupus erythematosus.

Granel J, Fernandes H, Bader-Meunier B, Guth A, Richer O, Pillet P, Leverger G, Ducassou S, Fahd M, Pasquet M, Garnier N, Barlogis V, Guitton C, Jeziorski E, Thomas C, Bayart S, Cheikh N, Paillard C, Abou Chahla W, Chastagner P, Neven B, Millot F, Lejeune J, Li Thiao Te V, Armari-Alla C, Briandet C, Carausu L, Deparis M, Piguet C, Benadiba J, Marie-Cardine A, Stephan JL, Pellier I, Pluchart C, Doré E, Michaux K, Heritier S, Leblanc TM, Aladjidi N

Blood. 2024 01 16;:

Educational outcomes in siblings of childhood leukemia survivors: Factors associated with school difficulties and comparison with general population.

Faust C, Auquier P, Gandemer V, Bertrand Y, Tabone MD, Ansoborlo S, Baruchel A, Bonneau J, Dalle JH, Chastagner P, Kanold J, Poirée M, Theron A, Olivier L, Pellier I, Michel G, Berbis J

Cancer Med. 2024 01 10;:

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.

Moreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V, Zwaan CM, Nysom K, Gerber N, Castellano A, Laureys G, Ladenstein R, Rössler J, Makin G, Murphy D, Morland B, Vaidya S, Thebaud E, van Eijkelenburg N, Tweddle DA, Barone G, Tandonnet J, Corradini N, Chastagner P, Paillard C, Bautista FJ, Gallego Melcon S, De Wilde B, Marshall L, Gray J, Burchill SA, Schleiermacher G, Chesler L, Peet A, Leach MO, McHugh K, Hayes R, Jerome N, Caron H, Laidler J, Fenwick N, Holt G, Moroz V, Kearns P, Gates S, Pearson ADJ, Wheatley K,

J Clin Oncol. 2024 01 8;:JCO2300458

METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors.

André N, Deley MCL, Léguillette C, Probst A, Willems L, Travers R, Aerts I, Faure-Conter C, Revond-Riviere G, Min V, Geoerger B, Chastagner P, Entz-Werlé N, Leblond P

Eur J Cancer. 2024 01 6;198:113525

A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors.

Marques Da Costa ME, Zaidi S, Scoazec JY, Droit R, Lim WC, Marchais A, Salmon J, Cherkaoui S, Morscher RJ, Laurent A, Malinge S, Mercher T, Tabone-Eglinger S, Goddard I, Pflumio F, Calvo J, Redini F, Entz-Werlé N, Soriano A, Villanueva A, Cairo S, Chastagner P, Moro M, Owens C, Casanova M, Hladun-Alvaro R, Berlanga P, Daudigeos-Dubus E, Dessen P, Zitvogel L, Lacroix L, Pierron G, Delattre O, Schleiermacher G, Surdez D, Geoerger B

Commun Biol. 2023 09 18;6(1):949

Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study.

Berlanga P, Ndounga-Diakou LA, Aerts I, Corradini N, Ducassou S, Strullu M, de Carli E, André N, Entz-Werle N, Raimbault S, Roumy M, Renouard M, Gueguen G, Plantaz D, Reguerre Y, Cleirec M, Petit A, Puiseux C, Andry L, Klein S, Bodet D, Kanold J, Briandet C, Halfon-Domenech C, Nelken B, Piguet C, Saumet L, Chastagner P, Benadiba J, Millot F, Pluchart C, Schneider P, Thouvenin S, Gambart M, Serre J, Abbou S, Leruste A, Cayzac H, Gandemer V, Laghouati S, Vassal G

JAMA Netw Open. 2023 07 3;6(7):e2321568

Neurocognitive and radiological follow-up of children under 5 years of age treated for medulloblastoma according to the HIT-SKK protocol.

Merlin MS, Schmitt E, Mezloy-Destracque M, Dufour C, Riffaud L, Puiseux C, De Carli E, Bodet D, Icher C, Doz F, Faure-Conter C, Pagnier A, Pluchart C, Thouvenin-Doulet S, Lejeune J, Nguyen Thi PL, Chastagner P

J Neurooncol. 2023 05 12;:

Impact of childhood leukemia on siblings: their long-term perception of family functioning and its relationship with their psychosocial characteristics using structural equation modeling.

Faust C, Auquier P, Bertrand Y, Tabone MD, Ansoborlo S, Baruchel A, Gandemer V, Dalle JH, Chastagner P, Kanold J, Poirée M, Theron A, Plat G, Pellier I, Michel G, Berbis J

J Cancer Surviv. 2023 05 10;:

Age-related immune cell dynamics influence outcomes after allogeneic haematopoietic cell transplantation.

Jandin A, Pochon C, Campidelli A, D'Aveni M, Kicki C, Notarantonio AB, Roth Guepin G, Mbuyi TA, Feugier P, Chastagner P, Schweitzer C, de Carvalho Bittencourt M, Rubio MT, Pagliuca S

Br J Haematol. 2023 04 24;:

Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX).

Leblond P, Tresch-Bruneel E, Probst A, Néant N, Solas C, Sterin A, Boulanger T, Aerts I, Faure-Conter C, Bertozzi AI, Chastagner P, Entz-Werlé N, De Carli E, Deley ML, Bouche G, André N

Cancers (Basel). 2023 03 28;15(7):

Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia.

Pincez T, Fernandes H, Pasquet M, Abou Chahla W, Granel J, Héritier S, Fahd M, Ducassou S, Thomas C, Garnier N, Barlogis V, Jeziorski E, Bayart S, Chastagner P, Cheikh N, Guitton C, Paillard C, Lejeune J, Millot F, Li-Thiao Te V, Mallebranche C, Pellier I, Neven B, Armari-Alla C, Carausu L, Piguet C, Benadiba J, Pluchart C, Stephan JL, Deparis M, Briandet C, Doré E, Marie-Cardine A, Leblanc T, Leverger G, Aladjidi N

Am J Hematol. 2023 03 7;:

Symptomatic osteonecrosis in French survivors of childhood and adolescent leukemia: a clinical and MRI study of LEA cohort.

Huault A, Michel G, Charon V, Chouklati K, Domenech C, Chastagner P, Dalle JH, Paillard C, Ducassou S, Poirée M, Plat G, Tabone MD, Kanold J, Baruchel A, Berger C, Pellier I, Plantaz D, Theron A, Mustafa A, Auquier P, Gandemer V

Pediatr Hematol Oncol. 2023 02 23;:1-17

Retrospective National "Real Life" Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol.

Winnicki C, Leblond P, Bourdeaut F, Pagnier A, Paluenzela G, Chastagner P, Duhil-De Benaze G, Min V, Sudour-Bonnange H, Piette C, Entz-Werle N, Chabaud S, André N

J Clin Med. 2023 02 10;12(4):

Radiosensitization with Gadolinium Chelate-Coated Gold Nanoparticles Prevents Aggressiveness and Invasiveness in Glioblastoma.

Durand M, Chateau A, Jubréaux J, Devy J, Paquot H, Laurent G, Bazzi R, Roux S, Richet N, Reinhard-Ruch A, Chastagner P, Pinel S

Int J Nanomedicine. 2023 01 13;18:243-261

NRP1 inhibition modulates radiosensitivity of medulloblastoma by targeting cancer stem cells.

Douyère M, Gong C, Richard M, Pellegrini-Moïse N, Daouk J, Pierson J, Chastagner P, Boura C

Cancer Cell Int. 2022 12 1;22(1):377

Brothers and sisters of childhood acute leukemia survivors: Their long-term quality of life and its determinants.

Faust C, Auquier P, Hamidou Z, Bertrand Y, Tabone MD, Ansoborlo S, Baruchel A, Gandemer V, Dalle JH, Chastagner P, Kanold J, Poirée M, Sirvent N, Plat G, Pellier I, Michel G, Berbis J

Cancer Med. 2022 10 20;:

Life engagement and anxiety-depressive symptoms in adolescents and young adults with or without a cancer history and their mothers: A dyadic analytic approach.

Lemétayer F, Florquin M, Chastagner P, Lanfranchi JB

Eur J Cancer Care (Engl). 2022 10 17;:e13745

Fertility discussions and concerns in childhood cancer survivors, a systematic review for updated practice.

El Alaoui-Lasmaili K, Nguyen-Thi PL, Demogeot N, Lighezzolo-Alnot J, Gross MJ, Mansuy L, Chastagner P, Koscinski I

Cancer Med. 2022 10 12;:

Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.

Hamimed M, Leblond P, Dumont A, Gattacceca F, Tresch-Bruneel E, Probst A, Chastagner P, Pagnier A, De Carli E, Entz-Werlé N, Grill J, Aerts I, Frappaz D, Bertozzi-Salamon AI, Solas C, André N, Ciccolini J

Cancer Chemother Pharmacol. 2022 06 25;:

Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma.

Hamimed M, Gattacceca F, André N, Tresch-Bruneel E, Probst A, Chastagner P, Pagnier A, De Carli E, Entz-Werlé N, Grill J, Aerts I, Frappaz D, Bertozzi-Salamon AI, Solas C, Leblond P

Br J Clin Pharmacol. 2021 Oct 28;:

Childhood ovarian non-seminomatous germ cell tumors: A Highly Curable Disease With Few Long-Term Treatment-Related Toxicities. Results of the French TGM95 study.

Pavone R, Pacquement H, Pasquet M, Sudour-Bonnange H, Hameury F, Sarnacki S, Chastagner P, Faure-Conter C, Poirée M, Taque S, Patte C, Fresneau B

Int J Cancer. 2021 Jun 19;:

The detrimental invasiveness of glioma cells controlled by gadolinium chelate-coated gold nanoparticles.

Durand M, Lelievre E, Chateau A, Berquand A, Laurent G, Carl P, Roux S, Chazee L, Bazzi R, Eghiaian F, Jubreaux J, Ronde P, Barberi-Heyob M, Chastagner P, Devy J, Pinel S

Nanoscale. 2021 May 12;:

Flow cytometric contribution to detect neuroblastoma cells.

Lesesve JF, Latger-Cannard V, Mansuy L, Chastagner P, Broseus J

Pediatr Blood Cancer. 2021 Mar 10;:e28999

Bone Mineral Density Evolution and Its Determinants in Long-term Survivors of Childhood Acute Leukemia: A Leucémies Enfants Adolescents Study.

Tabone MD, Kolta S, Auquier P, Vercasson C, Chastagner P, Kanold J, Rohrlich PS, Bertrand Y, Baruchel A, Plantaz D, Gandemer V, Ducassou S, Petit A, Paillard C, Leverger G, Dalle JH, Berbis J, Roux C, Michel G

Hemasphere. 2021 Feb;5(2):e518

Neuropilin-1: A Key Protein to Consider in the Progression of Pediatric Brain Tumors.

Douyère M, Chastagner P, Boura C

Front Oncol. 2021 ;11:665634

Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5.

Dufour C, Foulon S, Geoffray A, Masliah-Planchon J, Figarella-Branger D, Guerrini-Rousseau L, Faure-Conter C, Icher C, Bertozzi AI, Leblond P, Akbaraly T, Bourdeaut F, André N, Chappé C, Schneider P, De Carli E, Chastagner P, Berger C, Lejeune J, Soler C, Entz-Werlé N, Delisle MB

Neuro Oncol. 2020 Dec 30;:

CEREBELLAR SWELLING AFTER SURGERY FOR MEDULLOBLASTOMA WITH LEPTOMENINGEAL DISSEMINATION IN CHILDREN. A CASE BASED-UPDATE.

Todeschi J, Stella I, Entz-Werle N, Coca HA, Joud A, Chastagner P, Proust F, Klein O

Neurochirurgie. 2020 Dec 16;:

Optic pathway tumor in children: toward a new classification for neurosurgical use.

Stella I, Helleringer M, Joud A, Chastagner P, Thomas R, Klein O

Neurochirurgie. 2020 Nov 21;:

Langerhans cell histiocytosis with extensive lung destruction: Not always the worst-case scenario.

Le Rouzic MA, Mansuy L, Galloy MA, Della Valle V, Kambouchner M, Tazi A, Chastagner P, Donadieu J

Pediatr Pulmonol. 2020 Nov 19;:

Childhood Langerhans cell histiocytosis with severe lung involvement: a nationwide cohort study.

Le Louet S, Barkaoui MA, Miron J, Galambrun C, Aladjidi N, Chastagner P, Kebaili K, Armari-Alla C, Lambilliotte A, Lejeune J, Moshous D, Della Valle V, Sileo C, Ducou Le Pointe H, Chateil JF, Renolleau S, Piloquet JE, Portefaix A, Epaud R, Chiron R, Bugnet E, Lorillon G, Tazi A, Emile JF, Donadieu J, Héritier S

Orphanet J Rare Dis. 2020 09 9;15(1):241

Chest computed tomography findings for a cohort of children with pulmonary Langerhans cell histiocytosis.

Della Valle V, Donadieu J, Sileo C, Barkaoui MA, Héritier S, Brisse H, Boutry N, Tréguier C, Chateil JF, Petit P, Pracros JP, Chastagner P, Boyer C, Veillon F, Durand C, Mounayer C, Kambouchner M, Brauner M, Tazi A, Epaud R, Ducou le Pointe H

Pediatr Blood Cancer. 2020 Jul 25;:e28496

Relapsing intracranial germ cell tumours warrant retreatment.

Callec L, Lardy-Cleaud A, Guerrini-Rousseau L, Alapetite C, Vignon L, Chastagner P, Frappaz D, Faure-Conter C

Eur. J. Cancer. 2020 Jul 22;136:186-194

Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure.

Siebel C, Würthwein G, Lanvers-Kaminsky C, André N, Berthold F, Castelli I, Chastagner P, Doz F, English M, Escherich G, Frühwald MC, Graf N, Groll AH, Ruggiero A, Hempel G, Boos J

BMC Pharmacol Toxicol. 2020 May 28;21(1):37

Combined use of multiparametric flow cytometry and cytomorphology to enhance detection of neuroblastoma metastatic cells in bone marrow.

Manenq C, Lesesve JF, Dreumont N, Massin F, Salignac S, Mansuy L, Chastagner P, Latger-Cannard V, Broséus J

Int J Lab Hematol. 2019 Dec 10;:

Exploring heterogeneity of adrenal cortical tumors in children: The French pediatric rare tumor group (Fracture) experience.

Picard C, Faure-Conter C, Leblond P, Brugières L, Thomas-Teinturier C, Hameury F, Defachelles AS, Verschuur A, Brisse HJ, Sarnacki S, Dijoud F, Reguerre Y, Chastagner P, Carton M, Orbach D

Pediatr Blood Cancer. 2019 Nov 18;:e28086

Rapid fully-automated assay for routine molecular diagnosis of mutations for personalized therapy of low grade gliomas.

Merlin MS, Gilson P, Rouyer M, Chastagner P, Doz F, Varlet P, Leroux A, Gauchotte G, Merlin JL

Pediatr Hematol Oncol. 2019 Oct 23;:1-12

Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.

Le Teuff G, Castaneda-Heredia A, Dufour C, Jaspan T, Calmon R, Devos A, McHugh K, Leblond P, Frappaz D, Aerts I, Zwaan CM, Ducassou S, Chastagner P, Verschuur A, Corradini N, Casanova M, Rubie H, Riccardi R, Le Deley MC, Vassal G, Geoerger B,

Pediatr Blood Cancer. 2019 Oct 8;:e28032

SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor.

Heng-Maillard MA, Verschuur A, Aschero A, Dabadie A, Jouve E, Chastagner P, Leblond P, Aerts I, De Luca B, André N

Pediatr Blood Cancer. 2019 Mar 28;:e27693

Agreement between clinicoradiological signs at diagnosis and radiohistological analysis after neoadjuvant chemotherapy of suspected Wilms tumor rupture: Consequences on therapeutic choices.

Le Rouzic MA, Mansuy L, Galloy MA, Champigneulle J, Bernier V, Chastagner P

Pediatr Blood Cancer. 2019 Feb 17;:e27674

Effectiveness of antibacterial prophylaxis in children with acute leukemia: A report from a single institution over a 20-year period.

Chastagner P, Michel D, Contet A, Lozniewski A, Hadou T, Schmitt C, Phulpin A, Fouyssac F, Mansuy L

Arch Pediatr. 2018 Oct 16;:

Association between genetic polymorphisms and platinum-induced ototoxicity in children.

Lui G, Bouazza N, Denoyelle F, Moine M, Brugières L, Chastagner P, Corradini N, Entz-Werle N, Vérité C, Landmanparker J, Sudour-Bonnange H, Pasquet M, Verschuur A, Faure-Conter C, Doz F, Tréluyer JM

Oncotarget. 2018 Jul 20;9(56):30883-30893

Validation of a high performance functional assay for individual radiosensitivity in pediatric oncology: a prospective cohort study (ARPEGE).

Bernier-Chastagner V, Hettal L, Gillon V, Fernandes L, Huin-Schohn C, Vazel M, Tosti P, Salleron J, François A, Cérimèle E, Perreira S, Peiffert D, Chastagner P, Vogin G

BMC Cancer. 2018 Jul 6;18(1):719

Genetic polymorphisms of Th2 interleukins, history of asthma or eczema and childhood acute lymphoid leukaemia: Findings from the ESCALE study (SFCE).

Bonaventure A, Orsi L, Rudant J, Goujon-Bellec S, Leverger G, Baruchel A, Bertrand Y, Nelken B, Pasquet M, Michel G, Sirvent N, Chastagner P, Ducassou S, Thomas C, Besse C, Hémon D, Clavel J

Cancer Epidemiol. 2018 Jun 5;55:96-103

Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.

Ferry I, Kolesnikov-Gauthier H, Oudoux A, Cougnenc O, Schleiermacher G, Michon J, Bogart E, Chastagner P, Proust S, Valteau-Couanet D, Defachelles AS

J. Pediatr. Hematol. Oncol.. 2018 Apr 10;:

Prevalence and characteristics of metabolic syndrome in adults from the French childhood leukemia survivors' cohort: a comparison with controls from the French population.

Oudin C, Berbis J, Bertrand Y, Vercasson C, Thomas F, Chastagner P, Ducassou S, Kanold J, Tabone MD, Paillard C, Poirée M, Plantaz D, Dalle JH, Gandemer V, Thouvenin S, Sirvent N, Saultier P, Béliard S, Leverger G, Baruchel A, Auquier P, Pannier B, Michel G

Haematologica. 2018 Apr;103(4):645-654

Stimulation of medulloblastoma stem cells differentiation by a peptidomimetic targeting neuropilin-1.

Gong C, Valduga J, Chateau A, Richard M, Pellegrini-Moïse N, Barberi-Heyob M, Chastagner P, Boura C

Oncotarget. 2018 Mar 16;9(20):15312-15325

Medulloblastoma: A turning point from fundamental advances to improved survival and decreased sequelae.

Chastagner P

Neurochirurgie. 2018 Feb 12;:

Medulloblastoma: A turning point from fundamental advances to improved survival and decreased sequelae.

Chastagner P, Klein O

Neurochirurgie. 2018 Feb 9;:

Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial.

Verschuur A, Heng-Maillard MA, Dory-Lautrec P, Truillet R, Jouve E, Chastagner P, Leblond P, Aerts I, Honoré S, Entz-Werle N, Sirvent N, Gentet JC, Corradini N, André N

Front Pharmacol. 2018 ;9:00950

Spinal cord tumors in children: A review of 21 cases treated at the same institution.

Merlot I, Francois J, Marchal JC, Joud A, Guerbouz R, Chastagner P, Klein O

Neurochirurgie. 2017 Sep;:

Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study).

Chisholm JC, Merks JHM, Casanova M, Bisogno G, Orbach D, Gentet JC, Thomassin-Defachelles AS, Chastagner P, Lowis S, Ronghe M, McHugh K, van Rijn RR, Hilton M, Bachir J, Fürst-Recktenwald S, Geoerger B, Oberlin O,

Eur. J. Cancer. 2017 Jul;83:177-184

Unexpected acute renal injury after high-dose etoposide phosphate and total body irradiation in children undergoing hematopoietic stem cell transplantation.

Cordero C, Loboda C, Clerc-Urmès I, Clément L, Pochon C, Chastagner P

Pediatr Blood Cancer. 2017 Jul;:

NUT carcinoma in children and adults: A multicenter retrospective study.

Lemelle L, Pierron G, Fréneaux P, Huybrechts S, Spiegel A, Plantaz D, Julieron M, Dumoucel S, Italiano A, Millot F, Le Tourneau C, Leverger G, Chastagner P, Carton M, Orbach D

Pediatr Blood Cancer. 2017 Jun;:

[Need for an overall reflexion on personalized medicine in pediatric oncology].

Chastagner P

Arch Pediatr. 2017 Mar;:

Late effects in survivors of infantile acute leukemia: a study of the L.E.A program.

Gandemer V, Bonneau J, Oudin C, Berbis J, Bertrand Y, Tabone MD, Ducassou S, Chastagner P, Brethon B, Dalle JH, Thouvenin S, Poiree M, Plantaz D, Kanold J, Sirvent N, Lutz P, Hamidou Z, Baruchel A, Leverger G, Auquier P, Michel G

Blood Cancer J. 2017 Jan;7(1):e518

Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.

Sirvent A, Auquier P, Oudin C, Bertrand Y, Bohrer S, Chastagner P, Poirée M, Kanold J, Thouvenin S, Perel Y, Plantaz D, Tabone MD, Yakouben K, Gandemer V, Lutz P, Sirvent N, Vercasson C, Berbis J, Chambost H, Leverger G, Baruchel A, Michel G

Bone Marrow Transplant.. 2017 Jan;52(1):80-87

Employment in French young adult survivors of childhood leukemia: an LEA study (for Leucemies de l'Enfant et de l'Adolescent-childhood and adolescent leukemia).

Berbis J, Reggio C, Michel G, Chastagner P, Bertrand Y, Kanold J, Sirvent N, Plantaz D, Baruchel A, Tabone MD, Garnier F, Lehucher-Michel MP, Auquier P

J Cancer Surviv. 2016 Dec;10(6):1058-1066

Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. study.

Oudin C, Auquier P, Bertrand Y, Chastagner P, Kanold J, Poirée M, Thouvenin S, Ducassou S, Plantaz D, Tabone MD, Dalle JH, Gandemer V, Lutz P, Sirvent A, Villes V, Barlogis V, Baruchel A, Leverger G, Berbis J, Michel G

Haematologica. 2016 Jun;101(6):747-56

[Assessment of daily quality of life in children surviving cancer].

Lemétayer F, Lanfranchi JB, Chastagner P

Arch Pediatr. 2016 May;23(5):447-54

[Multidisciplinarity, education, and training in pediatric oncology-hematology].

Vassal G, Landman-Parker J, Baruchel A, Bergeron C, Rubie H, Coze C, Chastagner P, Leverger G, Bertrand Y, Valteau-Couanet D, Michon J, Couanet D, Rivière AM, Avenell D, Pérel Y, Doz F

Arch Pediatr. 2015 Dec;22(12):1217-22

Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma.

Chastagner P, Devictor B, Geoerger B, Aerts I, Leblond P, Frappaz D, Gentet JC, Bracard S, Andre N

Cancer Chemother Pharmacol. 2015 Aug;76(2):425-32

Deep sequencing reveals occurrence of sub-clonal ALK mutations in neuroblastoma at diagnosis.

Bellini A, Bernard V, Leroy Q, Rio-Frio T, Pierron G, Combaret V, Lapouble E, Clement N, Rubie H, Thebaud E, Chastagner P, Defachelles AS, Bergeron C, Buchbinder N, Taque S, Auvrignon A, Valteau-Couanet D, Michon J, Janoueix-Lerosey I, Delattre O, Schleiermacher G

Clin Cancer Res. 2015 Jun 9. pii: clincanres.0423.2015.

[Ewing sarcoma located in the mandible: A case report].

Hernandez M, Droz D, Mansuy L, Simon E, Chastagner P

Arch Pediatr. 2015 Jun;22(6):626-9

Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program.

Barlogis V, Auquier P, Bertrand Y, Chastagner P, Plantaz D, Poiree M, Kanold J, Berbis J, Oudin C, Vercasson C, Allouche M, Tabone MD, Thouvenin-Doulet S, Saumet L, Chambost H, Baruchel A, Leverger G, Michel G

Haematologica. 2015 May;100(5):e186-9

Health status and quality of life of long-term survivors of childhood acute leukemia: the impact of central nervous system irradiation.

Benadiba J, Michel G, Auquier P, Chastagner P, Kanold J, Poiree M, Plantaz D, Padovani L, Berbis J, Barlogis V, Contet A, Chambost H, Sirvent N

J Pediatr Hematol Oncol. 2015 Mar;37(2):109-16

Cohort Profile: the French childhood cancer survivor study for leukaemia (LEA Cohort).

Berbis J, Michel G, Baruchel A, Bertrand Y, Chastagner P, Demeocq F, Kanold J, Leverger G, Plantaz D, Poiree M, Stephan JL, Auquier P, Contet A, Dalle JH, Ducassou S, Gandemer V, Lutz P, Sirvent N, Tabone MD, Thouvenin-Doulet S

Int J Epidemiol. 2015 Feb;44(1):49-57

Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study.

Horwitz M, Auquier P, Barlogis V, Contet A, Poiree M, Kanold J, Bertrand Y, Plantaz D, Galambrun C, Berbis J, Villes V, Chastagner P, Sirvent N, Oudin C, Michel G

Br J Haematol. 2015 Feb;168(4):518-25

ARID5B, IKZF1 and Non-Genetic Factors in the Etiology of Childhood Acute Lymphoblastic Leukemia: The ESCALE Study.

Rudant J, Orsi L, Bonaventure A, Goujon-Bellec S, Baruchel A, Petit A, Bertrand Y, Nelken B, Pasquet M, Michel G, Saumet L, Chastagner P, Ducassou S, Reguerre Y, Hemon D, Clavel J

PLoS One. 2015 Mar 25;10(3):e0121348

Preclinical studies of pegylated- and non-pegylated liposomal forms of doxorubicin as radiosensitizer on orthotopic high-grade glioma xenografts.

Chastagner P, Sudour H, Mriouah J, Barberi-Heyob M, Bernier-Chastagner V, Pinel S

Pharm Res. 2015 Jan;32(1):158-66

Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.

Millot F, Guilhot J, Baruchel A, Petit A, Leblanc T, Bertrand Y, Mazingue F, Lutz P, Verite C, Berthou C, Galambrun C, Nicolas Sirvent, Yacouben K, Chastagner P, Gandemer V, Reguerre Y, Couillault G, Khalifeh T, Rialland F

Eur J Cancer. 2014 Dec;50(18):3206-11.

Incidence and survival of children with central nervous system primitive tumors in the French National Registry of Childhood Solid Tumors.

Desandes E, Guissou S, Chastagner P, Lacour B

Neuro Oncol. 2014 Jul;16(7):975-83.

Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.

Valteau-Couanet D, Le Deley MC, Bergeron C, Ducassou S, Michon J, Rubie H, Le Teuff G, Coze C, Plantaz D, Sirvent N, Bouzy J, Chastagner P, Hartmann O

Pediatr Blood Cancer. 2014 Jun;61(6):977-81

Health status of childhood leukemia survivors who received hematopoietic cell transplantation after BU or TBI: an LEA study.

Bernard F, Auquier P, Herrmann I, Contet A, Poiree M, Demeocq F, Plantaz D, Galambrun C, Barlogis V, Berbis J, Garnier F, Sirvent N, Kanold J, Chastagner P, Chambost H, Michel G

Bone Marrow Transplant. 2014 May;49(5):709-16

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.

Di Giannatale A, Dias-Gastellier N, Devos A, Mc Hugh K, Boubaker A, Courbon F, Verschuur A, Ducassoul S, Malekzadeh K, Casanova M, Amoroso L, Chastagner P, Zwaan CM, Munzer C, Aerts I, Landman-Parker J, Riccardi R, Le Deley MC, Geoerger B, Rubie H

Eur J Cancer. 2014 Jan;50(1):170-7

Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study.

Alloin AL, Barlogis V, Auquier P, Contet A, Poiree M, Demeocq F, Herrmann I, Villes V, Bertrand Y, Plantaz D, Kanold J, Chastagner P, Chambost H, Sirvent N, Michel G

Br J Haematol. 2014 Jan;164(1):94-100

A French cohort of childhood leukemia survivors: impact of hematopoietic stem cell transplantation on health status and quality of life.

Berbis J, Michel G, Chastagner P, Sirvent N, Demeocq F, Plantaz D, Barlogis V, Contet A, Poiree M, Kanold J, Galambrun C, Baumstarck K, Chambost H, Auquier P

Biol Blood Marrow Transplant. 2013 Jul;19(7):1065-72

Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood.

Girard P, Auquier P, Barlogis V, Contet A, Poiree M, Demeocq F, Berbis J, Herrmann I, Villes V, Sirvent N, Kanold J, Chastagner P, Chambost H, Plantaz D, Michel G

Haematologica. 2013 Jul;98(7):1089-97

Focus on invasive mucormycosis in paediatric haematology oncology patients: a series of 11 cases.

Phulpin-Weibel A, Rivier A, Leblanc T, Bertrand Y, Chastagner P

Mycoses. 2013 May;56(3):236-40

Are ARID5B and IKZF1 polymorphisms also associated with childhood acute myeloblastic leukemia: the ESCALE study (SFCE)?

Rudant J, Orsi L, Bonaventure A, Goujon-Bellec S, Corda E, Baruchel A, Bertrand Y, Nelken B, Robert A, Michel G, Sirvent N, Chastagner P, Ducassou S, Rialland X, Hemon D, Leverger G, Clavel J

Leukemia. 2013 Mar;27(3):746-8

Fertility treatments, congenital malformations, fetal loss, and childhood acute leukemia: the ESCALE study (SFCE).

Rudant J, Amigou A, Orsi L, Althaus T, Leverger G, Baruchel A, Bertrand Y, Nelken B, Plat G, Michel G, Sirvent N, Chastagner P, Ducassou S, Rialland X, Hemon D, Clavel J

Pediatr Blood Cancer. 2013 Feb;60(2):301-8

Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.

Pinel S, Mriouah J, Vandamme M, Chateau A, Plenat F, Guerin E, Taillandier L, Bernier-Chastagner V, Merlin JL, Chastagner P

PLoS One. 2013 Jul 18;8(7):e68333

Genetic polymorphisms and childhood acute lymphoblastic leukemia: GWAS of the ESCALE study (SFCE).

Orsi L, Rudant J, Bonaventure A, Goujon-Bellec S, Corda E, Evans TJ, Petit A, Bertrand Y, Nelken B, Robert A, Michel G, Sirvent N, Chastagner P, Ducassou S, Rialland X, Hemon D, Milne E, Scott RJ, Baruchel A, Clavel J

Leukemia. 2012 Dec;26(12):2561-4

[Medulloblastoma in childhood: an heterogeneous disease requiring treatment adjustments to known risk factors].

Orbach D, Chastagner P, Bourdeaut F, Doz F

Rev Prat. 2012 Sep;62(7):989-90.

Folic acid supplementation, MTHFR and MTRR polymorphisms, and the risk of childhood leukemia: the ESCALE study (SFCE).

Amigou A, Rudant J, Orsi L, Goujon-Bellec S, Leverger G, Baruchel A, Bertrand Y, Nelken B, Plat G, Michel G, Haouy S, Chastagner P, Ducassou S, Rialland X, Hemon D, Clavel J

Cancer Causes Control. 2012 Aug;23(8):1265-77

Involvement of the TGFbeta pathway in the regulation of alpha5 beta1 integrins by caveolin-1 in human glioblastoma.

Cosset EC, Godet J, Entz-Werle N, Guerin E, Guenot D, Froelich S, Bonnet D, Pinel S, Plenat F, Chastagner P, Dontenwill M, Martin S

Int J Cancer. 2012 Aug 1;131(3):601-11

Integrin alpha5beta1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.

Janouskova H, Maglott A, Leger DY, Bossert C, Noulet F, Guerin E, Guenot D, Pinel S, Chastagner P, Plenat F, Entz-Werle N, Lehmann-Che J, Godet J, Martin S, Teisinger J, Dontenwill M

Cancer Res. 2012 Jul 15;72(14):3463-70

Growth hormone treatment impact on growth rate and final height of patients who received HSCT with TBI or/and cranial irradiation in childhood: a report from the French Leukaemia Long-Term Follow-Up Study (LEA).

Isfan F, Kanold J, Merlin E, Contet A, Sirvent N, Rochette E, Poiree M, Terral D, Carla-Malpuech H, Reynaud R, Pereira B, Chastagner P, Simeoni MC, Auquier P, Michel G, Demeocq F

Bone Marrow Transplant. 2012 May;47(5):684-93

Development of an osteosarcoma following dental extraction after allogeneic stem cell transplantation.

Phulpin B, Marchettic N, Mansuyd L, Coffinet L, Lucas C, Dolivet G, Chastagner P, Prevost J

Rev Laryngol Otol Rhinol (Bord). 2012;133(4-5):237-40.

A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age.

Monnereau-Laborde S, Munzer C, Valteau-Couanet D, Ansoborlo S, Coze C, Chastagner P, Rubie H, Demeocq F, Stephan JL, Hartmann O, Perel Y

Pediatr Blood Cancer. 2011 Dec 1;57(6):965-71

Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities.

Le Meignen M, Auquier P, Barlogis V, Sirvent N, Contet A, Simeoni MC, Galambrun C, Poiree M, Chastagner P, Play B, Villes V, Berbis J, Chambost H, Bordigoni P, Michel G

Blood. 2011 Aug 11;118(6):1481-9

[Medulloblastomas: review].

Taillandier L, Blonski M, Carrie C, Bernier V, Bonnetain F, Bourdeaut F, Thomas IC, Chastagner P, Dhermain F, Doz F, Frappaz D, Grill J, Guillevin R, Idbaih A, Jouvet A, Kerr C, Donadey FL, Padovani L, Pallud J, Sunyach MP

Rev Neurol (Paris). 2011 May;167(5):431-48

Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia.

Oudin C, Simeoni MC, Sirvent N, Contet A, Begu-Le Coroller A, Bordigoni P, Curtillet C, Poiree M, Thuret I, Play B, Massot MC, Chastagner P, Chambost H, Auquier P, Michel G

Blood. 2011 Apr 28;117(17):4442-8

Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect.

Urien S, Doz F, Giraud C, Rey E, Gentet JC, Chastagner P, Vassal G, Corradini N, Auvrignon A, Leblond P, Rubie H, Treluyer JM

Cancer Chemother Pharmacol. 2011 Mar;67(3):597-603

Radiosensitizing properties of bortezomib depend on therapeutic schedule.

Labussiere M, Pinel S, Vandamme M, Plenat F, Chastagner P

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):892-900

[A case report of frosted branch angiitis associated with aseptic meningitis in a young boy].

Chaume A, Lemelle I, Chastagner P, Angioi K

J Fr Ophtalmol. 2011 Feb;34(2):129.e1-5

Effect of adapted physical activity sessions in the hospital on health-related quality of life for children with cancer: a cross-over randomized trial.

Speyer E, Herbinet A, Vuillemin A, Briancon S, Chastagner P

Pediatr Blood Cancer. 2010 Dec 1;55(6):1160-6.

Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.

Rubie H, Geoerger B, Frappaz D, Schmitt A, Leblond P, Ndiaye A, Aerts I, Le Deley MC, Gentet JC, Paci A, Chastagner P, Dias N, Djafari L, Pasquet M, Chatelut E, Landman-Parker J, Corradini N, Vassal G

Eur J Cancer. 2010 Oct;46(15):2763-70

Effect of adapted physical activity on health-related quality of life among hospitalized children and adolescents (the ACTIV'HOP randomized controlled trial): design and methods.

Speyer E, Vuillemin A, Herbinet A, Chastagner P, Briancon S

Contemp Clin Trials. 2010 Mar;31(2):165-71

Fertility and pregnancy outcome after abdominal irradiation that included or excluded the pelvis in childhood tumor survivors.

Sudour H, Chastagner P, Claude L, Desandes E, Klein M, Carrie C, Bernier V

Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):867-73

[Diffuse intrinsic brain stem glioma in children: current treatment and future directions]

Leblond P, Vinchon M, Bernier-Chastagner V, Chastagner P

Arch Pediatr. 2010 Feb;17(2):159-65

Retrospective French nationwide survey of childhood aggressive vascular anomalies of bone, 1988-2009.

Heritier S, Le Merrer M, Jaubert F, Bigorre M, Gillibert-Yvert M, de Courtivron B, Ziade M, Bertrand Y, Carrie C, Chastagner P, Bost-Bru C, Leonard JC, Ouache M, Boccon-Gibod L, Mary P, de Blic J, Pin I, Wendling D, Revillon Y, Houdoin V, Forin V, Lepointe HD, Languepin J, Wagnon J, Epaud R, Fauroux B, Donadieu J

Orphanet J Rare Dis. 2010 Feb 3;5:3.

Agreement between children with cancer and their parents in reporting the child's health-related quality of life during a stay at the hospital and at home.

Speyer E, Herbinet A, Vuillemin A, Chastagner P, Briancon S

Child Care Health Dev. 2009 Jul;35(4):489-95.

VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the Societe Francaise des Cancers de l'Enfant (SFCE).

Bourdeaut F, de Carli E, Timsit S, Coze C, Chastagner P, Sarnacki S, Delattre O, Peuchmaur M, Rubie H, Michon J

Pediatr Blood Cancer. 2009 May;52(5):585-90.

Interest of liposomal doxorubicin as a radiosensitizer in malignant glioma xenografts

Labussiere M, Aarnink A, Pinel S, Taillandier L, Escanye JM, Barberi-Heyob M, Bernier-Chastagner V, Plenat F, Chastagner P

Anticancer Drugs. 2008 Nov;19(10):991-8.

Proteasome inhibition by bortezomib does not translate into efficacy on two malignant glioma xenografts

Labussiere M, Pinel S, Delfortrie S, Plenat F, Chastagner P

Oncol Rep. 2008 Nov;20(5):1283-7.

Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies.

Geoerger B, Doz F, Gentet JC, Mayer M, Landman-Parker J, Pichon F, Chastagner P, Rubie H, Frappaz D, Le Bouil A, Gupta S, Vassal G

J Clin Oncol. 2008 Sep 20;26(27):4394-400.

Pontine tumors

Klein O, Chastagner P, Joud A, Marchal JC, Lena G

J Neurosurg Pediatr. 2008 May;1(5):423-4; author reply 424-5.

Clinical Practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)

Ray-Coquard I, Kassab-Chahmi D, Casadevall N, Chastagner P, Marchal C, Marec-Berard P, Misset JL

Bull Cancer. 2008 Apr;95(4):433-41.

[Germ-cell tumors of the central nervous system in childhood: retrospective study of 13 patients]

Voirin J, Klein O, Chastagner P, Moret C, Vignaud JM, Auque J, Marchal JC

Neurochirurgie. 2008 Apr;54(2):55-62

[Cancer in children: epidemiologic, diagnostic and therapeutic characteristics]

Orbach D, Chastagner P, Doz F

Rev Prat. 2008 Mar 15;58(5):557-63.

[Standards & options: recommendations for the use of erythropoiesis-stimulating agents (ESA) in anaemic cancer patients undergoing radiotherapy (2007 update)]

Marchal C, Misset JL, Casadevall N, Marec-Berard P, Chastagner P, Kassab-Chahmi D, Ray-Coquard I

Cancer Radiother. 2008 Mar;12(2):126-33.

Standards, Options: Recommendations for the use of erythropoiesis-stimulating agents (ESA : epoetin alfa, epoetin beta, darbepoetin) in anaemic patients with cancer: 2007 update

Ray-Coquard I, Kassab-Chahmi D, Casadevall N, Chastagner P, Marchal C, Marec-Berard P, Misset JL

Oncologie. 2008 Feb;10(2):160-6

Birth characteristics and childhood malignant central nervous sytem tumors: the ESCALE study (French Society for Childhood Cancer).

Mallol-Mesnard N, Menegaux F, Lacour B, Hartmann O, Frappaz D, Doz F, Bertozzi AI, Chastagner P, Hemon D, Clavel J

Cancer Detect Prev. 2008;32(1):79-86

Measurement of hypoxia using invasive oxygen-sensitive electrode, pimonidazole binding and F-18-FDG uptake in anaemic or erythropoietin-treated mice bearing human glioma xenografts

Scigliano S, Pinel S, Poussier S, Fouyssac F, Plenat F, Karcher G, Chastagner P

Int J Oncol. 2008 Jan;32(1):69-77.

Contrast-enhanced ultrasound in fibro-lamellar hepatocellular carcinoma: A case report

Mandry D, Bressenot A, Galloy MA, Chastagner P, Branchereau S, Claudon M

Ultraschall Med. 2007 Dec;28(6):547-52.

Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study.

Chastagner P, Kalifa C, Doz F, Bouffet E, Gentet JC, Ruchoux MM, Bracard S, Desandes E, Frappaz D

Pediatr Blood Cancer. 2007 Nov;49(6):803-7.

Pharmacokinetic of liposomal anthracyclin

Chastagner P, Legrand P

Oncologie. 2007 Mar;9 Suppl. 1:S28-32

High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol.

Dufour C, Grill J, Lellouch-Tubiana A, Puget S, Chastagner P, Frappaz D, Doz F, Pichon F, Plantaz D, Gentet JC, Raquin MA, Kalifa C

Eur J Cancer. 2006 Nov;42(17):2939-45

Incidence and prognostic value of tumour cells detected by RT-PCR in peripheral blood stem cell collections from patients with Ewing tumour.

Vermeulen J, Ballet S, Oberlin O, Peter M, Pierron G, Longavenne E, Laurence V, Kanold J, Chastagner P, Lejars O, Blay JY, Marec-Berard P, Michon J, Delattre O, Schleiermacher G

Br J Cancer. 2006 Nov 20;95(10):1326-33

Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study.

Verlooy J, Mosseri V, Bracard S, Tubiana AL, Kalifa C, Pichon F, Frappaz D, Chastagner P, Pagnier A, Bertozzi AI, Gentet JC, Sariban E, Rialland X, Edan C, Bours D, Zerah M, Le Gales C, Alapetite C, Doz F

Eur J Cancer. 2006 Nov;42(17):3004-14

Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts.

Pinel S, Chastagner P, Merlin JL, Marchal C, Taghian A, Barberi-Heyob M

J Neurooncol. 2006 Jan;76(1):31-8.

Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study.

Bernier-Chastagner V, Grill J, Doz F, Bracard S, Gentet JC, Marie-Cardine A, Luporsi E, Margueritte G, Lejars O, Laithier V, Mechinaud F, Millot F, Kalifa C, Chastagner P

Cancer. 2005 Dec 15;104(12):2792-7.

[Evans' syndrome: a retrospective study from the ship (French Society of Pediatric Hematology and Immunology) (36 cases)].

Blouin P, Auvrignon A, Pagnier A, Thuret I, Antoni G, Bader-Meunier B, Le Deist F, Chastagner P, Aladjidi N, Pellier I, Bertrand Y, Behar C, Landmann-Parker J, Leverger G, Perel Y

Arch Pediatr. 2005 Nov;12(11):1600-7

Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.

Geoerger B, Vassal G, Doz F, O'Quigley J, Wartelle M, Watson AJ, Raquin MA, Frappaz D, Chastagner P, Gentet JC, Rubie H, Couanet D, Geoffray A, Djafari L, Margison GP, Pein F

Br J Cancer. 2005 Sep 5;93(5):529-37.

Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience.

Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, Marec-Berard P, Pacquement H, Chastagner P, Defaschelles AS, Hartmann O

Cancer. 2005 Sep 1;104(5):1100-9.

Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.

Grill J, Sainte-Rose C, Jouvet A, Gentet JC, Lejars O, Frappaz D, Doz F, Rialland X, Pichon F, Bertozzi AI, Chastagner P, Couanet D, Habrand JL, Raquin MA, Le Deley MC, Kalifa C

Lancet Oncol. 2005 Aug;6(8):573-80.

Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: results of the SFOP NBL90 study.

Bergeron C, Dubourg L, Chastagner P, Mechinaud F, Plouvier E, Desfachelles AS, Dusol F, Pautard B, Edan C, Plantaz D, Froehlich P, Rubie H

Pediatr Blood Cancer. 2005 Jul;45(1):32-6.

Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study.

Oyharcabal-Bourden V, Kalifa C, Gentet JC, Frappaz D, Edan C, Chastagner P, Sariban E, Pagnier A, Babin A, Pichon F, Neuenschwander S, Vinchon M, Bours D, Mosseri V, Le Gales C, Ruchoux M, Carrie C, Doz F

J Clin Oncol. 2005 Jul 20;23(21):4726-34.